Brief: Alloy Therapeutics Enters Into Multi-Target Collaboration And License Agreement With Biogen For Use Of Alloy’S Anticlastic™ Aso Platform
07/04/2026 11:07
April 7 (Reuters) - Biogen Inc BIIB.O: ALLOY THERAPEUTICS ENTERS INTO MULTI-TARGET COLLABORATION AND LICENSE AGREEMENT WITH BIOGEN FOR USE OF ALLOY’S ANTICLASTIC™ ASO PLATFORM ALLOY: THROUGH THIS COLLABORATION, BIOGEN WILL APPLY PLATFORM TO ADVANCE ANTISENSE THERAPEUTICS AGAINST MULTIPLE UNDISCLOSED TARGETS Source text: ID:nBwb1tz68a Further company coverage: BIIB.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Biogen
See all newsHealth Rounds: Old cancer drug may help restore fertility for certain women
U.S. STOCKS ON THE MOVE-FactSet, Moderna, Goldman Sachs
U.S. STOCKS ON THE MOVE-Biogen, Incyte, Quantum Cyber
Biogen rises; co scales back drug programs acquired through $5.6 bln Apellis deal
Biogen scales back Apellis programs, trims research roles after $5.6 billion buyout